Cooper CL, Hatashita H, Corsi DJ, Parmar P, Corrin R, Garber G

Language: English
References: 24
Page: 874-880
PDF size: 145.41 Kb.

ABSTRACT

Introduction. Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to healthcare. Materials and methods. A cohort database analysis was performed on patients followed at The Ottawa Hospital and Regional Viral Hepatitis Program between January 2012 and August 2016. We compared patient characteristics, fibrosis work-up and antiviral treatment outcomes in TM (n = 157) and non-TM (n = 1,130) patients (The Ottawa Hospital Viral Hepatitis Outpatient Clinic) residing in Eastern Ontario. Results. TM patients were more often infected with genotype 3 (25.9% vs. 16.4%), were more commonly Indigenous (7.0% vs. 2.2%) had a history of injection drug use (70.1% vs. 54.9%) and incarceration (46.5% vs 35.5%). Groups were comparable in age (48.9 years), gender (63.7% male) and cirrhotic stage (24.0%). 59.2% of TM patients underwent transient elastography during regional outreach blitzes compared to 61.8% of non-TM patients (p = 0.54). Overall, half as many TM patients initiated antiviral therapy as non-TM patients (27.4% vs. 53.8%, p ‹ 0.001). The introduction of DAA regimens is bridging this gap (22.2% of TM patients vs. 34.3% of non-TM patients). SVR rates with interferon-free, DAA regimens were 94.7% and 94.8% in TM and non-TM groups (p = 0.99). Conclusion. Our TM program engages and retains a population that faces many barriers to effective HCV treatment. TM patients initiated HCV therapy and achieved high SVR rates comparable to those obtained using traditional models of care.

REFERENCES

1. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013; 56:1078-84. doi: cis1202 [pii] 10.1093/cid/cis1202.

2. Nazareth S, Kontorinis N, Muwanwella N, Hamilton A, Leembruggen N, Cheng WS. Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth. J Telemed Telecare 2013; 19: 101-6. doi: jtt.2012.120612 [pii] 10.1258/jtt.2012.120612.

3. Rossaro L, Aoki C, Yuk J, Prosser C, Goforth J, Martinez F. The evaluation of patients with hepatitis C living in rural California via telemedicine. Telemed J E Health 2008; 14: 1127- 9. doi: 10.1089/tmj.2008.0029.

4. Rossaro L, Torruellas C, Dhaliwal S, Botros J, Clark G, Li CS, Minoletti MM. Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California. Dig Dis Sci 2013; 58: 3620-5. doi: 10.1007/s10620-013-2810-y.

5. Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10- year follow-up of a community-based hepatitis C cohort. J Fam Pract 2002; 51: 135-40. doi: jfp_0202_ [pii].

6. You A, Kawamoto J, Smith JP. A pharmacist-managed telemedicine clinic for hepatitis C care: a descriptive analysis. J Telemed Telecare 2014; 20: 99-101. doi: 1357633X13519043 [pii] 10.1177/1357633X13519043.

7. Young JD, Patel M, Badowski M, Mackesy-Amiti ME, Vaughn P, Shicker L, Puisis M, et al. Improved Virologic Suppression With HIV Subspecialty Care in a Large Prison System Using Telemedicine: An Observational Study With Historical Controls. Clin Infect Dis 2014. doi: ciu222 [pii] 10.1093/cid/ciu222.

8. Parmar P, Mackie D, Varghese S, Cooper C. Use of telemedicine technologies in the management of infectious diseases: a review. Clin Infect Dis 2015; 60: 1084-94. doi: 10.1093/ cid/ciu1143.

9. Arora S, Thornton K, Jenkusky SM, Parish B, Scaletti JV. Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico. Public Health Rep 2007; (122 Suppl. 2): 74-7.

10. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-207. doi: 10.1056/NEJMoa1009370.

11. DeMaio J, Schwartz L, Cooley P, Tice A. The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project. Clin Infect Dis 2001; 33: 2082-4. doi: CID010655 [pii] 10.1086/324506.

12. DeMaio J, Sharma D. Tuberculosis therapy and telemedicine. Expert Opin Pharmacother 2002; 3: 1283-8. doi: 10.1517/ 14656566.3.9.1283.

13. Gassanov MA, Feldman LJ, Sebastian A, Kraguljac MJ, Rea E, Yaffe B. The use of videophone for directly observed therapy for the treatment of tuberculosis. Can J Public Health 2013; 104: e272.

14. Khatri K, Haddad M, Anderson D. Project ECHO: replicating a novel model to enhance access to hepatitis C care in a community health center. J Health Care Poor Underserved 2013; 24: 850-8. doi: S154868691320032X [pii] 10.1353/ hpu.2013.0093.

15. Rossaro L, Tran TP, Ransibrahmanakul K, Rainwater JA, Csik G, Cole SL, Prosser CC, et al. Hepatitis C videoconferencing: the impact on continuing medical education for rural healthcare providers. Telemed J E Health 2007; 13: 269-77. doi: 10.1089/tmj.2006.0050.

16. 16. Saifu HN, Asch SM, Goetz MB, Smith JP, Graber CJ, Schaberg D, Sun BC. Evaluation of human immunodeficiency virus and hepatitis C telemedicine clinics. Am J Manag Care 2012; 18: 207-12. doi: 63938 [pii].

17. Wade VA, Karnon J, Eliott JA, Hiller JE. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLoS One 2012; 7: e50155. doi: 10.1371/journal.pone.0050155 PONE-D-12-16544 [pii].

18. Elbert NJ, van Os-Medendorp H, van Renselaar W, Ekeland AG, Hakkaart-van Roijen L, Raat H, Nijsten TE, et al. Effectiveness and cost-effectiveness of ehealth interventions in somatic diseases: a systematic review of systematic reviews and meta-analyses. J Med Internet Res 2014; 16: e110. doi: v16i4e110 [pii] 10.2196/jmir.2790.

19. Eron L. Telemedicine: the future of outpatient therapy? Clin Infect Dis 2010; (51 Suppl. 2): S224-30. doi: 10.1086/ 653524.

20. Public Health Agency of Canada: Hepatitis C in Canada: 2005-2010 Surveillance Report. In: Centre for Communicable Diseases and Infection Control; Infectious Disease Prevention and Control Branch ed.: Public Health Agency of Canada, 2011.

21. Statistics Canada. Census Profile. Available at: URL. Access: December 2 2016.

22. Pampalon R, Hamel D, Gamache P, Raymond G. A deprivation index for health planning in Canada. Chronic Dis Can 2009; 29: 178-91.

23. Leon A, Caceres C, Fernandez E, Chausa P, Martin M, Codina C, Rousaud A, et al. A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study. PLoS One 2011:(6):e14515. doi: 10.1371/journal.pone.0014515.

24. Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 2016; 4: E605- E614. doi: 10.9778/cmajo.20160008.